- Home
- APPS vs CABA Comparison
APPS vs CABA Comparison
Compare APPS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- CABA
- Stock Information
- Founded
- APPS N/A
- CABA 2017
- Country
- APPS United States
- CABA United States
- Employees
- APPS N/A
- CABA N/A
- Industry
- APPS Multi-Sector Companies
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APPS Miscellaneous
- CABA Health Care
- Exchange
- APPS Nasdaq
- CABA Nasdaq
- Market Cap
- APPS 428.8M
- CABA 491.9M
- IPO Year
- APPS N/A
- CABA 2019
- Fundamental
- Price
- APPS $2.92
- CABA $3.98
- Analyst Decision
- APPS Hold
- CABA Strong Buy
- Analyst Count
- APPS 2
- CABA 9
- Target Price
- APPS $5.25
- CABA $31.44
- AVG Volume (30 Days)
- APPS 3.4M
- CABA 869.3K
- Earning Date
- APPS 11-06-2024
- CABA 08-08-2024
- Dividend Yield
- APPS N/A
- CABA N/A
- EPS Growth
- APPS N/A
- CABA N/A
- EPS
- APPS N/A
- CABA N/A
- Revenue
- APPS $516,105,000.00
- CABA N/A
- Revenue This Year
- APPS $2.50
- CABA N/A
- Revenue Next Year
- APPS $9.57
- CABA N/A
- P/E Ratio
- APPS N/A
- CABA N/A
- Revenue Growth
- APPS N/A
- CABA N/A
- 52 Week Low
- APPS $1.39
- CABA $3.47
- 52 Week High
- APPS $7.33
- CABA $26.35
- Technical
- Relative Strength Index (RSI)
- APPS 48.98
- CABA 31.72
- Support Level
- APPS $2.57
- CABA $4.03
- Resistance Level
- APPS $2.99
- CABA $6.14
- Average True Range (ATR)
- APPS 0.23
- CABA 0.37
- MACD
- APPS -0.09
- CABA -0.05
- Stochastic Oscillator
- APPS 33.47
- CABA 1.42
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.